Innovative Sciences is a new, broad-based research company currently specializing in a
finalizing and marketing proprietary and patented technologies for biological fluid monitoring
methodologies useful for improving patient compliance with medication regimes and early
diagnosis of renal disease. The proposed patents replace our prior ones and greatly expand the
field of application.

Briefly, this summary describes the varied technological innovations marketed or ready to
be introduced by the company. The company’s founder, Dr. Michael Kell, has an excellent
“track” record of creating and patenting new technologies which have generated billions of
dollars annually. He also has the “knack” of finding ways to refute older methods and so
eliminate competition by older methodologies. Dr. Kell generally looks for a time period in the
market equal to two patent cycles or 40 years.

The Company is seeking investors as limited partners so to finalize the new patent
technology and begin any necessary clinical studies. The Company would like to provide 30% of
its shares to investors as a joint venture limited partnership. In particular, the Company is
interested in attracting alumni of MIT, Harvard, and Caltech as advisers and future officers and


Vision and Value Statement

The founder of the Company has been long aware that the human species is “futureinsight
blind,” an evolutionary psychological flaw contributing to our current political, social,
and scientific ineffectiveness in establishing “workable and feasible” contingency plans adequate
for dealing with our pending resource, population, and social catastrophes.

The long-term goal of the Company is to establish a sound body of visionary scientists,
sociologists, economists, and engineers able to “peer” into the potential future of mankind so to
prepare for and avert species-limiting situation by creating workable and just solutions to assure
the continuation of the psychosocial evolution of our species.
The Company proposes to accomplish such by creating a broad spectrum of multidisciplinary
research centers, each aligned with a major advanced institution of learning, both
self-funded and independent of third party influences so real changes will come in the future
which benefit all persons in a merit-based system.
Long-Term Mission Statement
The unifying mission of the Company is to “see into the future” so to create and develop
new technologies for alleviating major world problems in healthcare, energy, food, and other
critical areas. The founders visualize the eventual formation of a “top-notch” research institute
with multiple centers aligned cooperatively with domestic and international universities. By
aligning itself with the scientific expertise of the academic, basic sciences, both parties benefit.
The Company assures itself of the earliest familiarly with new basic scientific advances
so it can quickly visualize future commercial applications and begin development of such in a
timely and economic manner. The universities benefit by securing long-term income streams
freeing them of the need for high tuition and governmental influence.

Business and Growth Strategy

The Company is organized in Georgia and is a limited partnership; though, it is likely that
the founders will move eventually to a more scientific situs; most likely Boston, MA.
Seventy percent of the shares are held by the founders of the Company and thirty percent
will be offered to investors. None of the shares offered can be diluted. Shares may not be sold
unless approval is obtained from a majority of the other shareholders. Total partner shares ten

The proposed first round of investment is intended to secure approximately $12 million
dollars so to proceed with final development and patenting of its existing proprietary

Once the Company has established “ proof of principle and application methodologies” in
any new area, further monies will be sought via the formation of 50:50 joint ventures with
selective business entities who would financially benefit and who can fund any additional
research studies, including, animal and human clinical studies in healthcare or product R & D.

A reasonable portion of the Company’s future income will arise from “short-term”
solutions to well-described technical problems via licensing and selling of such “easy technology.
From income received from its ventures, the Company will fund its internal laboratories
(likely the most advanced and secretive work) and those of academia. All monies received in
excess of those needed for current expenditures and capital savings, will flow to the original


Fully Individualized Pharmacokinetic Monitoring

In the 1990s, Dr. Kell began developing clinical methodologies for therapeutic
monitoring of potentially dangerous or abusable medications employing random urine samples.
His initial work was focused upon patients prescribed pain (methadone, OxyContin, morphine
and others) and anti-anxiety medications (Valium, Xanax and others); since it was common for
such patients to over-use or sell their medications to other patients or on the street. Being that
Dr. Kell was employing urine as his monitoring matrix, it was necessary for him to concentrate
upon the biophysics of kidney function. Concurrently, in addition to his pharmacokinetic
inventions (how the body absorbs, metabolizes and excretes drugs and metabolites), Dr. Kell
found new and unique ways to diagnose early, preventable renal disease.

Dr. Kell’s early work generated a number of unique patents for accurate monitoring of
patient urine so to prove compliance and indirectly measure drug plasma concentrations so to
guide treatment decisions. Using this technology, over the past ten years, clinicians have been
using this technology to prevent drug diversion or misuse to other parties, to correlate plasma and
urine concentrations to therapeutic efficacy, to evaluate hepatic metabolism and minimize
morbidity and mortality, and uncover early renal disease.

In 2004, Sterling Partners became interested in commercializing Dr. Kell’s technology
and formed the medical laboratory, Ameritox, LLC. Its first and best product, RxGuardian,
established a standard in the industry for monitoring patients in pain clinics. By, 2010, Ameritox
was reported to be worth over a billion dollars.

Patent coverage for the original technology was due to expire around 2012-14, and
Ameritox decided to switch to another methodology called creatinine indexing. This
methodology was initially evaluated and discarded by Dr. Kell as it was extremely inaccurate–a
fact not well appreciated in the medical community. Dr. Kell will soon publish a technical paper
proving that creatinine indexing is a pseudoscience and must be discarded. This paper will
essentially disrupt the entire drug monitoring field for Ameritox and its competitors, who all use
creatinine indexing, resulting in a severe void for clinicians.

To address this eventual situation, Dr. Kell has finalized new patents supporting a
“second generation methodology,” such being far in advance of the older methodologies.
Moreover, it is highly unlikely that any other party will find a way to go around the new patents
for they arise from a fuller understanding of renal function and new theories.
Dr. Kell would like to find investors to enter into the therapeutic drug monitoring arena
so to capture the totality of the market, not only for pain medications, but for all drugs. His
original goal was to have urine monitoring become a standard technique for adjusting medication
levels, diagnosing early renal disease, uncovering potential drug reaction scenarios prior to their
occurrence, assuring that each and every treatment physician knows all the medications being
taken by his or her patient and so on.

His technological innovations are well accepted in the medical community and will help
to decrease medicine expenditures, lower health insurance, prevent adverse drug reactions,
uncover undiagnosed renal disease (which cannot be done today), assure that patients are
prescribed the proper medicines and so on.

Kell estimates that the developed North American and European market annually is
between five to ten billion dollars.

Eradication of Tumor Cell Populations Using Broad Manipulation
of Bioenergetic Pathways (bMOP) in the Post-Ehrlichism Era

Antineoplastic protocols generally employ the triad of chemotherapy, radiation and surgery so to
rid the body of proliferating, symptomatic, tumor burden and delaying tumor-associated
mortality. Sadly, tumor recurrence, drug resistence and post-treatment morbidity and mortality
remains unacceptably elevated. Bedazzled still, by the rubrica occultus of Paul Ehrlich’s
magical bullet or the alchemists lapis philosophis, traditional oncological research continues to
focus upon targeting specific pathways or single-point physicochemical differences betwixt
normal and cancer tissue. However, an increasing cohort of neo-oncologists are coming to the
realization that eradication of cancer will require multi-pathway intervention; for cancers are
creatures of Darwin, genetically and metabolically complex, self-promoting, symbiotic tumorstromal
alliances utilizing broad, temporally-evolving, biochemical adaptations to out-compete
healthy tissues. Here, we propose the first, comprehensive, neo-oncological protocol for
eradication of tumor source-stem cells and the end of tumor recurrence. Our approach is
seemingly paradoxical, combining nutrient hyperalimentation for intracellular acid loading,
selective enzyme blocking and polymodal interruption of cellular pH control, inducing apoptosis
of tumor tissue without untoward toxicity to healthy tissue. It is our sincere hope that our
‘paradoxical proposal’ will prove sufficiently exciting so to encourage full exploration and the
potential discovery of fully effective therapies to prevent and cure cancer.

Kell estimates that the developed North American and European market annually is
between five to ten billion dollars.

Detection of Early Renal Disease And Treatment to Arrest Progression

The present invention relates generally to diagnostic methodologies useful for early
detection of occult renal disease, initiation of medical treatment so to prevent or significantly
slow progression to End-Stage Renal Disease and the necessity for dialysis. The early detection
and treatment of renal disease will result in significant savings for third-party payers. It is also
useful for the general estimation of an individual’s current renal function, ambulatory or
hospitalized, and the adjustment of medications so to optimize efficacy and minimize morbidity
and mortality. More particularly, the present invention relates to utilization of simultaneous
measurements of serum and urine creatinine concentrations easily accomplished in an ambulatory
medical clinic or hospital for the accurate estimation of creatinine clearance and the glomerular
filtration rate. The invention can be used to improve the diagnostic accuracy of traditional
methodologies employing timed, urine collections and single or multiple serum creatinine
measurements for calculating creatinine clearance; though such measurements often being highly
erroneous do to inherent technical errors and unrecognized, biological variations in creatinine
serum levels during the day. It also does not require the utilization of other endogenous and
exogenous markers to determine GFR.

Kell estimates that the developed North American and European market annually is more
two billion dollars.

New Combustion Engine Cycle

Several years ago, Dr. Kell discovered an operational cycle for an internal combustion engine
which has not previously been recognized. Following extensive calculations this engine, this
new operational cycle will increase fuel efficiency by a minimum of 30% and will produce
greatly reduced N0x. Such engine may not require catalytic convertors and requires very little
new technology. The design can be a retrofit.

Currently, the world annual production of new automobile engines is 60 million, new
truck engines is 6 million , new boat and airplane combustion engines is 5 million and other
engines at least 5 million. At a licensing fee of $100, the company would generate on the order
of $7 billion annually. The annual retrofit market is at least as large.

Other Areas of Current Interest

Dr. Kell is also interested in the feasibility of producing Animalia - Plantae symbionts
and the commercialization of nuclear fusion for producing necessary rare earth metals.


Current founding ownership of the Company is sixty-five percent to the general
partner, the Institute, and (2) five percent to Mr. Robert Hughes, Esq., who is the director responsible for presenting the company to future investment partners and legal and general business matters. Mr. Hughes is actively involved in the funding market in Boston. Dr. Kell is the managing director for the Company.

The company will hire office and administrative staff as needed. It will also work to
engage personnel at MIT and Harvard as to technical matters.  CV are available for Dr. Kell and Mr. Hughes upon request.

Due to the highly technical and intellectual nature of the Company’s business and vision,
it needs to hire the most creative, visionary, and intellectually motivated persons available. The
company is designed solely on a meritorious basis so to be just to all current and future
employees. The Company desires that each employee arrive at his or her “best” position within
the company so to be most productive. The Company will eventually institute a profit sharing
and incentive program to encourage expansion and
income retention.


For a long time, the Institute has been involved in locating funding for socially responsible research--much of it by Dr. Kell.  Current projects for which we are seeking investment partners are briefly described below.  If interested in helping please contact the Institute and we shall get back to you promptly.

In the near future we shall provide a method for crowd funding of our psychospiritual and scientific enterprises.

​​​the freedom exercises